All
Vitiligo and Retinal Detachment: Is There a Connection?
People with vitiligo face a higher risk of retinal detachment, according to a study in Taiwan.
Psychological Stress Exacerbates Brain Activities in Female Patients With Atopic Dermatitis
Functional magnetic resonance imaging response was utilized to test motor, somatosensory association cortex, perception, and sensory integration processing in a recent study.
Previewing Editorial Advisory Board Member Sessions at IMCAS World Congress 2024
Among the many sessions to be held at the IMCAS World Congress 2024 in Paris, France, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.
Discovering Dermatology Times: January 2024 Topical Treatments for Vitiligo Supplement
Learn more about the in-depth topics covered in the January 2024 topical treatments for vitiligo supplement of Dermatology Times.
Dupilumab Plus Antihistamines Beats Antihistamines Alone in Treating CSU
Patients with chronic spontaneous urticaria saw improvement in itch and hive severity when dupilumab was added to their antihistamines in a 24-week study.
Is CPS the Solution for Refractory Plantar Warts?
An immunosuppressed patient with refractory plantar warts showed improvement following cantharidinpodophyllotoxin-salicylic acid (CPS) monotherapy.
Verrica Receives Permanent J-Code for Ycanth for Molluscum Contagiosum
The Centers for Medicare & Medicaid Services has issued a permanent J-code for the first and only FDA-approved treatment for molluscum contagiosum.
Marcelo Bigal, MD, PhD: VENT-03's Modality Offers Hope for Targeted Therapy in Skin Disorders
Marcelo Bigal, MD, PhD, discusses VENT-03's potential as a small molecule therapeutic in dermatology, among other fields.
Efinaconazole Demonstrates Superior Transungual Penetration Compared to Other Antifungal Treatments
Topical antifungals, whether FDA-approved or available over-the-counter, exhibited more effective penetration through cellulose disks than cadaver nails.
POLL: Are You Attending IMCAS World Congress 2024?
Let us know if you plan to attend IMCAS World Congress 2024.
The Weekly Roundup: January 22-26
ICYMI, this week we had news about the completion of LEO Pharma's acquisition of Timber Pharmaceuticals, research pointing to melanoma overdiagnosis in White patients, artificial intelligence in skin cancer detection, and more.
Light-Responsive Drug Delivery System for Skin Cancer Holds Promise
The novel nanofiber-based system holds promise for future nanotech applications in health care, researchers claim.
'Considerable Number’ of Pregnancies Reported Among Women and Girls Using Isotretinoin in Germany
A population-based study found a 63% increase in isotretinoin use in the years 2004 to 2019, and an increase in isotretinoin-exposed pregnancies as well.
The Year Ahead in Dermatology
So far, 2024 is shaping up to be just as busy as 2023 with new dermatology innovations, approvals, and data. Review what's still to come in 2024.
Higher Scalp Hair Loss Linked to Noticeable Gaps or Absence in Eyebrow and Eyelash Hair in Patient Study
A poster analyzing the BRAVE-AA study population was presented at Maui Derm Hawaii 2024.
How to Handle Social Media Retaliation
A patient's social media post has gone viral and has been seen by thousands. Dr Derm is concerned this malicious act may ruin his career. What can he do?
Study Points Toward Stark Disparity of Academic Papers Referencing Sunscreen in Patients With Skin of Color
A poster from Maui Derm Hawaii revealed an even more significant disparity than researchers anticipated.
Patient Preferences in Atopic Dermatitis Treatment
Patients with moderate to severe AD gave their opinions in a survey on treatment options and their tradeoffs. Itch control topped the list of patient concerns.
Pointers With Portela: Effective Wart Treatments
In this week’s Pointers With Portela, the 208SkinDoc reviews various treatment methods for permanent wart removal.
New Year Report Card for Dermatologists and Their Practices
This article delves into 5 critical areas that dermatologists should focus on for a comprehensive 2024 report card.
Researchers Say Evidence Points to Need for Terminology Change in Axillary and Inguinal Lentiginosis in Neurofibromatosis
Researchers from Pyeongchon, Korea, argue that evidence points to the need for a change in the terminology of "freckling," according to a poster from Maui Derm Hawaii.
Trifarotene Yields Significant Improvements in Post-Inflammatory Hyperpigmentation
A poster presented at Maui Derm Hawaii delved into the efficacy and safety of trifarotene 50µg/g cream in acne vulgaris and PIH.
Tailoring AD Management Advice to Lifestyles and Hobbies
In a recent Dermatology Times Case-Based Roundtable Meeting, Tina Bhutani, MD, MAS, shared intriguing cases and insights about atopic dermatitis treatment challenges faced by patients with different lifestyles and hobbies.
Dosing Starts in Phase 3 ASC40 Trial For Acne Treatment
Investigators explained how the trial is structured to inhibit facial sebum production and inflammation among nearly 500 study participants.
Targeted Social Media Recruitment Efficient, Effective in Trial for Low-Grade Actinic Keratosis
Online patient recruitment methods were effective in a proof-of-concept trial involving patients with low-grade AK.
POLL: Do You Utilize Artificial Intelligence When Completing Skin Checks?
Click here to answer this week's poll.
Jordan Miller, MD: 2024 Dermatology Predictions
Advancements in assistance from artificial intelligence include ambient listening to take notes during physician and patient conversations.
Melanoma Overdiagnosis Rising Among White Patients
Almost 90% of white men and 85% of white women who received a diagnosis of melanoma in 2018 were likely overdiagnosed, according to a new study.
Photoprotective Awareness, Behaviors Lacking Among Lebanese Population
Approximately half of patients presenting to dermatology clinics in Beirut reported the use of sunscreen.
LEO Pharma Completes Key Asset Acquisition, Including TMB-001, From Timber Pharmaceuticals
The finalized acquisition comes 5 months after Timber Pharmaceuticals filed for chapter 11 bankruptcy.